CA-JUMPCODE-GENOMICS
13.6.2024 08:01:34 CEST | Business Wire | Press release
Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.
Under the terms of the agreement Jumpcode and Takara Bio USA have each granted the other party a license to use their IP in exchange for an agreed royalty payment. The financial terms were not disclosed. The companies’ combined IP comprises multiple patents and patent applications worldwide, including U.S. Patent 11,708,606, held by Jumpcode, and U.S. Patent 10,150,985, held by Takara Bio USA.
The companies’ cutting-edge technologies, sold under the DepleteX® and CRISPRclean brands by Jumpcode and as ZapR technology by Takara Bio USA, remove unwanted sequences from biological samples to enable the discovery and detection of novel molecules. This enables researchers to significantly improve the sensitivity of their RNA-seq libraries and provides significant cost savings by reducing the need to sequence unwanted abundant sequences.
The technology can be used in multiple research and translational applications and has the potential to be utilized to rapidly detect unknown, previously undetectable pathogens, which is critically important, particularly in the event of a future pandemic.
Commenting on the partnership Mike Salter, President and CEO of Jumpcode, said: “We are delighted to partner with Takara. Our combined technology is instrumental to scientists around the world enabling them to deliver groundbreaking research, and we are excited by its potential to transform the future of molecular biology. We look forward to working with Takara Bio USA as we focus on the global commercialisation of our products.”
Carol Lou, President & CEO of Takara Bio USA, said: “We are very pleased to be working with Jumpcode to bring together the innovative technology platforms and foundational IP of both companies. This agreement brings clarity for both Takara Bio USA’s and Jumpcode’s customers and partners and paves the way for both companies to combine their strengths to better enable genomics research.”
About Jumpcode Genomics
Jumpcode Genomics is changing genomics with technology that enables critical workflows for research and clinical applications to break through existing barriers. Our CRISPR-based technology removes uninformative sequences allowing for the sensitive detection of biologically relevant molecules. Combining this technology and next-generation sequencing, it’s now possible to search for and discover novel signals that were previously undetectable for greater insights and broadening the understanding of human biology. Discover what we can do at www.jumpcodegenomics.com. Follow Jumpcode on LinkedIn and Twitter @JumpcodeG.
About Takara Bio
Takara Bio USA, Inc. is a wholly owned subsidiary of Takara Bio Inc. that manufactured and distributes kits, reagents and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification and automated sample preparation.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612041634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform20.10.2026 17:00:00 CEST | Press release
The Cessna Grand Caravan EX Veris provides a high-fidelity, cost-effective solution for pilot development and expands training opportunities for one of the world’s most widely operated utility aircraft TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc., announced today the introduction of its Cessna Grand Caravan EX Veris Virtual Reality Flight Training Device (FTD), expanding the Veris product line to support one of the aviation industry's most versatile and widely utilized aircraft platforms. The announcement marks the first Caravan-configured training device offered within TRU Simulation's portfolio and reflects the company's continued investment in immersive aviation training technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020834162/en/ TRU Simulation introduces first Cessna Grand Caravan EX Flight Training Device on the Veris platform "The Veris p
92% of Compliance Leaders Want External Certification on AI Agents. None Exists for On-Chain Risk. Elliptic Just Built It, for Free.20.10.2026 16:00:00 CEST | Press release
Elliptic Institute launches the first certification in agentic AI for on-chain risk and compliance, grounded in the principles of the Elliptic Standard. Elliptic, the leader in on-chain risk management, today launched the first certification in governing AI agents for on-chain risk and financial crime compliance from the Elliptic Institute. The Certified Agentic On-Chain Risk Practitioner (CAORP) Foundation Level is free and open to anyone in the industry. The certification follows new Elliptic research in which 92% of senior risk, compliance and financial crime professionals said they would consider sending staff for external certification in agentic AI risk governance. The global research1 found a wide gap between that appetite and teams' current capability. Only 16% of respondents said they were very confident their team has the skills to govern an AI agent today, while 38% said they were not confident at all or had no capability yet. Nearly a third (31%) expect to send staff for ce
Xceedance Named a Leader and Star Performer in Everest Group’s Insurance Intermediaries Operations PEAK Matrix® Assessment 202620.10.2026 16:00:00 CEST | Press release
Assessment highlights Xceedance’s MGA capabilities, strategic acquisitions, and intermediary-focused technology ecosystem Xceedance today announced it has been named a Leader and Star Performer in the Everest Group Insurance Intermediaries Operations PEAK Matrix® Assessment 2026. The assessment evaluated 18 providers based on market impact and their vision and capability to deliver insurance intermediary operations services. Everest Group identified Xceedance’s support for MGAs and MGUs across entity setup and licensing, underwriting, policy administration, finance, analytics, and claims as a key strength. The report also highlighted enabling rapid program launches and scaling through a licensed MGA shell, configurable workflows, and integrated operations. “Xceedance brings deep insurance expertise and a growing breadth of capabilities to support MGAs, brokers, and Lloyd’s market participants,” said Dinesh Udawat, Practice Director, Everest Group. “Its strategic acquisitions have expan
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 15:30:00 CEST | Press release
Practitioner-led agenda shows Europe’s CHROs, talent leaders and HRIT teams how to redesign work with AI, agents and automation Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMP
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge20.10.2026 15:26:00 CEST | Press release
Documentary follows ThinkMD, VectorCam, and Huna, the three award recipients from the inaugural Future Health Impact Challenge, delivered in collaboration with MIT Solve Prospective participants can now register to receive information about the second Future Health Impact Challenge ahead of its upcoming full launch Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugural Impact Challenge demonstrates the transformative power of innovative solutions that accelerate the shift from reactive to anticipatory healthcare systems. With scenes filmed in Kigali, Medellín, São Paulo, Boston, and Abu Dhabi, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom